Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics
Antagonistic antibodies targeting the inhibitory immune-checkpoint receptor PD-1 or its
ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve …
ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve …
Roles of PD-1/PD-L1 pathway: signaling, cancer, and beyond
L Ai, A Xu, J Xu - Regulation of Cancer Immune Checkpoints: Molecular …, 2020 - Springer
Immunotherapies that target PD-1/PD-L1 axis have shown unprecedented success in a wide
variety of human cancers. PD-1 is one of the key coinhibitory receptors expressed on T cells …
variety of human cancers. PD-1 is one of the key coinhibitory receptors expressed on T cells …
[HTML][HTML] Regulation of PD-L1 expression in cancer and clinical implications in immunotherapy
X Ju, H Zhang, Z Zhou, Q Wang - American journal of cancer …, 2020 - ncbi.nlm.nih.gov
Abstract PD-1/PD-L1 immune checkpoint blockade therapy has become an effective method
for the treatment of cancers in the clinic. It has great clinical advantages and therapeutic …
for the treatment of cancers in the clinic. It has great clinical advantages and therapeutic …
Regulation and function of the PD-L1 checkpoint
Expression of programmed death-ligand 1 (PD-L1) is frequently observed in human
cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor …
cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor …
PD-L1 regulation revisited: impact on immunotherapeutic strategies
G Lucibello, B Mograbi, G Milano, P Hofman… - Trends in Molecular …, 2021 - cell.com
A particularly promising cancer treatment is the use of monoclonal antibodies (mAbs)
against immune checkpoints (ie, immune checkpoint inhibitors; ICIs). However, many …
against immune checkpoints (ie, immune checkpoint inhibitors; ICIs). However, many …
Posttranslational modifications of PD-L1 and their applications in cancer therapy
Posttranslational modifications (PTM) of PD-L1 have emerged as important regulatory
mechanisms that modulate immunosuppression in patients with cancer. In exposure to …
mechanisms that modulate immunosuppression in patients with cancer. In exposure to …
[HTML][HTML] PD1 signal transduction pathways in T cells
H Arasanz, M Gato-Cañas, M Zuazo, M Ibañez-Vea… - Oncotarget, 2017 - ncbi.nlm.nih.gov
The use of immune checkpoint inhibitors for the treatment of cancer is revolutionizing
oncology. Amongst these therapeutic agents, antibodies that block PD-L1/PD1 interactions …
oncology. Amongst these therapeutic agents, antibodies that block PD-L1/PD1 interactions …
PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome
Several cancers are highly refractory to conventional chemotherapy. The survival of tumors
in several cases is assisted by checkpoint immunomodulation to maintain the imbalance …
in several cases is assisted by checkpoint immunomodulation to maintain the imbalance …
Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy
C Feng, L Zhang, X Chang, D Qin, T Zhang - Frontiers in Immunology, 2023 - frontiersin.org
The immune checkpoint molecules programmed cell death receptor 1 (PD-1) and
programmed death ligand 1 (PD-L1) are one of the most promising targets for tumor …
programmed death ligand 1 (PD-L1) are one of the most promising targets for tumor …
The opportunities and challenges in immunotherapy: Insights from the regulation of PD-L1 in cancer cells
Q Lin, X Wang, Y Hu - Cancer Letters, 2023 - Elsevier
The immunosuppressive molecule programmed death-ligand 1 (PD-L1) is frequently
upregulated in human cancers. Binding of PD-L1 to its receptor, programmed death-1 (PD …
upregulated in human cancers. Binding of PD-L1 to its receptor, programmed death-1 (PD …
相关搜索
- pd l1 associated opportunities
- cancer immunotherapy pd 1
- pd l1 cancer therapy
- pd l1 posttranslational modifications
- pd l1 immunotherapeutic strategies
- pd l1 challenges in immunotherapy
- clinical outcome pd 1
- pd l1 clinical implications
- cancer cells opportunities and challenges
- pd l1 cancer immunotherapy
- pd l1 cancer cells
- pd l1 opportunities and challenges
- pd l1 tumor immunotherapy
- pd l1 clinical outcome